Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.48 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | HTR2B | P41595 | 2/20 | 0.42 |
| ▸ | PARP1 | P09874 | 2/20 | 0.42 |
| ▸ | CASP3 | P42574 | 2/20 | 0.42 |
| ▸ | CASP7 | P55210 | 2/20 | 0.42 |
| ▸ | CASP6 | P55212 | 2/20 | 0.42 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.42 |
| ▸ | CASP2 | P42575 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | FER | P16591 | 1/20 | 0.41 |
| ▸ | LTK | P29376 | 1/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.41 |
| ▸ | ANPEP | P15144 | 2/20 | 0.37 |
| ▸ | TDP2 | O95551 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3163873 | 0.81 | IDO1 (0.45) | GSK3BPARP1HSD17B10PDGFRAFER | |
| SCHEMBL4115729 | 0.81 | IDO1 (0.45) | GSK3BPARP1HSD17B10PDGFRAFER | |
| SCHEMBL3157916 | 0.81 | IDO1 (0.45) | GSK3BPARP1HSD17B10PDGFRAFER | |
| SCHEMBL11844924 | 0.78 | GSK3B (0.50) | GSK3BHTR2AHTR2CHTR2BPARP1 | |
| SCHEMBL5551044 | 0.76 | GSK3B (0.48) | GSK3BHTR2AHTR2CHTR2BPARP1 | |
| SCHEMBL28979780 | 0.76 | GSK3B (0.48) | GSK3BHTR2AHTR2CHTR2BPARP1 | |
| SCHEMBL30900692 | 0.75 | IDO1 (0.55) | GSK3BPARP1ANPEPIDO1L3MBTL1 | |
| SCHEMBL2543645 | 0.75 | IDO1 (0.55) | GSK3BPARP1ANPEPIDO1L3MBTL1 | |
| SCHEMBL11801695 | 0.74 | HSD17B10 (0.47) | GSK3BHTR2AHTR2CHTR2BCASP3 | |
| SCHEMBL15627439 | 0.74 | NSD2 (0.47) | HSD17B10SMN1; SMN2TNKS2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0243808-B1 | Isoquinolinediones, process for their preparation, and medicaments containing these compounds | BOEHRINGER MANNHEIM GMBH (DE) | 1994-07-13 | — | — | EP | claimed |
| EP-0243808-A2 | Isoquinolinediones, process for their preparation, and medicaments containing these compounds | Roche Diagnostics GmbH (DE) | 1987-11-04 | — | — | EP | claimed |
| US-8796458-B2 | Cyclohexylamine isoquinolone derivatives | SANOFI (FR) | 2014-08-05 | — | — | US | disclosed |
| US-8609691-B2 | Cyclohexylamin isoquinolone derivatives | SANOFI (FR) | 2013-12-17 | — | — | US | disclosed |
| US-20110251226-A1 | CYCLOHEXYLAMIN ISOQUINOLONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-10-13 | — | — | US | disclosed |
| EP-1912949-B1 | CYCLOHEXYLAMIN ISOQUINOLONE DERIVATIVES AS RHO-KINASE INHIBITORS | SANOFI SA (FR) | 2011-08-24 | — | — | EP | disclosed |
| US-20080242699-A1 | Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase inhibitors; Hypotensive agents; 6-(4-Amino-cyclohexyloxy)-2-(4-methoxy-benzyl)-7-propyl-2H-isoquinolin-1-one | SANOFI-AVENTIS (FR) | 2008-10-02 | — | — | US | disclosed |
| EP-1912949-A1 | CYCLOHEXYLAMIN ISOQUINOLONE DERIVATIVES AS RHO-KINASE INHIBITORS | Sanofi-Aventis (FR) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007012422-A1 | CYCLOHEXYLAMIN ISOQUINOLONE DERIVATIVES AS RHO-KINASE INHIBITORS | SANOFI-AVENTIS (DE) | 2007-02-01 | — | — | WO | disclosed |
| EP-0243808-B1 | Isoquinolinediones, process for their preparation, and medicaments containing these compounds | BOEHRINGER MANNHEIM GMBH (DE) | 1994-07-13 | — | — | EP | disclosed |
| US-4824835-A | Isoquinolinedione derivatives, pharmaceutical compositions and methods of use | BOEHRINGER MANNHEIM GMBH (DE) | 1989-04-25 | — | — | US | disclosed |
| EP-0243808-A2 | Isoquinolinediones, process for their preparation, and medicaments containing these compounds | Roche Diagnostics GmbH (DE) | 1987-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242699-A1 | Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase inhibitors; Hypotensive agents; 6-(4-Amino-cyclohexyloxy)-2-(4-methoxy-benzyl)-7-propyl-2H-isoquinolin-1-one | MYLK, MYLK2, ROCK1 | GSK3B 409/4885HTR2A 2345/4885HTR2C 2398/4885 |
| US-20110251226-A1 | CYCLOHEXYLAMIN ISOQUINOLONE DERIVATIVES | MYLK2, MYLK, MYLK3 | GSK3B 244/4885HTR2A 2965/4885HTR2C 3096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.